<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853992</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-2177</org_study_id>
    <secondary_id>2020-004961-38</secondary_id>
    <nct_id>NCT04853992</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria</brief_title>
  <official_title>Phase 2a Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with&#xD;
      cholinergic urticaria&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2a, randomised, double-blind, placebo-controlled, cross-over trial conducted&#xD;
      in Germany at 3-6 sites. Subjects will be randomised to one of two treatment sequences (A and&#xD;
      B). Each treatment period will last 7 days with a wash-out period of 7 days between&#xD;
      treatments. Half of the subjects will start with treatment A followed by treatment B while&#xD;
      the other half will start with treatment B followed by treatment A. A safety follow-up visit&#xD;
      will be performed 3 days after last dose of the tested medication.&#xD;
&#xD;
      The main assessment is an urticaria activity score. After a Pulse-controlled ergometry (PCE)&#xD;
      provocation test subjects will be rated on their number of wheals and their itch severity,&#xD;
      resulting in a sum score ranging from 0 to 6 points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each treatment period will last 7 days with a wash-out period of 7 days between treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in post-provocation Urticaria Activity Score</measure>
    <time_frame>After 7 days treatment period</time_frame>
    <description>The Urticaria Activity Score rates a participants' number of wheals and their itch severity on a scale from 0 to 6, with 6 being the most severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events per subject</measure>
    <time_frame>From treatment period start to 3 days after treatment end</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cholinergic Urticaria</condition>
  <arm_group>
    <arm_group_label>Active - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive active treatment for 7 days, followed by a washout period of 7 days and then placebo for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive placebo for 7 days, followed by a washout period of 7 days and then active treatment for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 152020</intervention_name>
    <description>LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.</description>
    <arm_group_label>Active - Placebo</arm_group_label>
    <arm_group_label>Placebo - Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 152020 placebo</intervention_name>
    <description>LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.</description>
    <arm_group_label>Active - Placebo</arm_group_label>
    <arm_group_label>Placebo - Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Subject with a history of Cholinergic urticaria diagnosis for ≥ 6 months&#xD;
&#xD;
          -  Subject has active and uncontrolled Cholinergic urticaria disease at the time of&#xD;
             screening and randomisation, as defined by the following:&#xD;
&#xD;
               1. Urticaria control test &lt; 12 at screening&#xD;
&#xD;
               2. Urticaria Activity Score post-provocation ≥ 3&#xD;
&#xD;
          -  Recent history (within 6 months of screening) with documented inadequate response to&#xD;
             standard dose as to marketing authorization of H1 antihistamines.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Other clearly dominating forms* of urticaria as aetiology for wheal and flare type&#xD;
             reactions&#xD;
&#xD;
             *These diseases are allowed as comorbidities, if cholinergic urticaria is the&#xD;
             dominating form of chronic urticaria,&#xD;
&#xD;
          -  Systemic immunosuppressive medications within 4 weeks prior to screening,&#xD;
&#xD;
          -  Drugs with antihistamine properties including H1 antihistamines and H2 antihistamines&#xD;
             1 week prior to randomisation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEO Pharma</last_name>
    <phone>(+1) 877-557-1168</phone>
    <email>clinicaltrialscontactus@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LEO Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEO Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEO Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEO Investigational Site</name>
      <address>
        <city>München</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data is available to request after results of the trial are available on leopharmatrials.com</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>https://leopharmatrials.com/en</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

